These results suggest that bortezomib can overcome therapeutic resistance and sensitize NSCLC cells to both cisplatin and radiation by enhancing DNA damage and apoptosis via downregulation of Smurf2. This evidence concerns the gene SMURF2 and non-small cell lung carcinoma.